Podcasts about Mowry

Citing China's possible mission to send Taikonauts around the moon, NASA Administrator Jared Isaacman told AIAA's ASCEND conference attendees that the launch cadence to the moon must increase. Laura Winter speaks with Clay Mowry, CEO of the American Institute of Aeronautics and Astronautics (AIAA) and immediate past president of the International Astronautical Federation (IAF).

There are many treatment options for people with relapsing MS. Patients should be carefully monitored to assess treatment response, and a change in treatment approach should be considered if safety concerns emerge. In this episode, Teshamae Monteith, MD, FAAN, speaks with Ellen M. Mowry, MD, MCR, and Daniel Ontaneda, MD, PhD, coauthors of the article "Treatment of Multiple Sclerosis" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Mowry is the director of the Multiple Sclerosis Experimental Therapeutics Program and a professor of neurology at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Ontaneda is the director of research at the Mellen Center for Multiple Sclerosis and a professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. Additional Resources Read the article: Treatment of Multiple Sclerosis Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @EllenMowryMD Full episode transcript available here Dr. Monteith: There are so many new treatment strategies for multiple sclerosis, which is a blessing, but it does come with the complexity of really just trying to nail down the approach. I just got finished talking to Drs Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis. We discussed relapses, weighing escalation versus early high-effective treatment and progressive disease. This is a must-listen-to podcast. I hope you enjoy it as much as I enjoyed talking to them.  Dr. Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr. Monteith: This is Dr. Teshamae Monteith. Today, I'm interviewing Ds Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Welcome, both of you. How are you?  Dr. Mowry: Great. And thank you so much for having us.  Dr. Monteith: Absolutely. So, why don't you both introduce yourself?  Dr. Ontaneda: All right. My name is Daniel Ontaneda. I'm a neurologist at the Cleveland Clinic. I spend the majority of my time doing research, but I still dedicate about a day a week to seeing people with MS in clinic.  Dr. Mowry: I'm Ellen Mowry. I'm also a neurologist, but practice at the Johns Hopkins University. And similar to Dan, I mostly work on research, but also have an active clinical care component, taking care of people with MS.  Dr. Monteith: Well, thank both of you for writing this article and being on our podcast. I assume you guys have probably known each other for quite a while now.  Dr. Mowry: Yes. Dr. Ontaneda: Yes. Dr. Monteith: What inspired you to get into multiple sclerosis research and then clinical care?  Dr. Ontaneda: I always loved neurology, and I think a lot of us who go into neurology are attracted to the complexity of the human brain and how the nervous system works. But what really hit home to me was a family member of mine who had multiple sclerosis, and he was being treated in a time where we really didn't have super effective disease-modifying medications. And so, as I went through my medical career, I always kind of kept an eye on what was happening with multiple sclerosis, and I started my training at a time where it was really flourishing in terms of the medications available, so that's what inspired me to go into MS. It's a disease that we can definitely treat, and you can change outcomes for people. So, that was it.  Dr. Monteith: Yeah, that personal experience can be very impactful.  Dr. Mowry: My journey started, actually, because I was thinking about whether I wanted to be a physician at all, and I happened to land, just after high school, a position with a neurologist who happened to mostly focus on multiple sclerosis and taking care of folks with multiple sclerosis. And by the end of the summer, I knew I wanted to go to med school and I wanted to be a neurologist and I wanted to work with people with MS. I thought I would be a clinician exclusively, but I think as time went on and I started to hear the consistent questions that people I served were asking in the clinic and realizing that those questions could be turned into research projects that could address their concerns, I moved more and more towards research. Dr. Monteith: Great. There are a lot of really detailed information in the article, so I think that research mind is very useful, and I see that in the writing. Why don't we talk about the goal of the article? Dr. Ontaneda: So, I think the goal of the article was to set out kind of what the large view of what treatment for multiple sclerosis looks like. And, you know, many times we divide the treatment of multiple sclerosis into these large pillars, and I think that's what we did in the article. The first was, you know, what do you do with a person who has an MS attack or relapse? The second is, what medications do we use to treat the relapsing forms of multiple sclerosis where there is a lot of acute inflammation, focal inflammatory lesions that are occurring? And then the final one is, what do you do with individuals who have a more progressive form of the disease where they're accruing disability slowly and gradually? Dr. Monteith: And what were some of the main points? Dr. Mowry: Dr. Okuda provided a really nice section on the treatment of acute relapses in multiple sclerosis, and it's important to understand what we talk about when we are saying "relapse". For people with MS, many symptoms can fluctuate and occur and then get better over time, and sometimes people with MS use the same term of "relapse" to describe those symptom fluctuations. As neurologists, when we're thinking about relapse, we're really trying to think about symptoms that can be attributed to new focal inflammatory events somewhere in the central nervous system. Typically, these are accompanied---if you were to get an MRI at the same time---by a new lesion or MS spot, as I like to call them, on MRI scan. And so, it's important to distinguish when somebody is talking about symptoms, whether they are true new symptoms that could be mapped to a place in the central nervous system. Because alternatively, a lot of people who've had attacks or relapses in the past can have what we call pseudo-relapses, and these are essentially recrudescence of old symptoms, typically in a similar pattern as what had occurred in the past. And these can be brought out by things like fever or infection, sometimes stress. And pseudo-relapses are not thought to be due to new development of immune system-induced injury and therefore would be less likely to respond to treatment; and in fact, treatment may be contraindicated for those events. We also talked a little bit in that article about how relapses are treated, talking about the use of high-dose steroids for true new relapses, but also kind of cautioning that those are not necessarily free of concerns, especially if you have a pseudo-relapse or there could be an infection going on. And that ultimately, the decision as to whether to treat a relapse really is a shared decision-making because it's thought that although the steroids can speed up recovery from a relapse, they may not have a major impact on ultimate recovery. And so, a lot of the shared decision-making comes in here because for a mild relapse, you might choose to forego a course of high-dose steroids.  Dr. Monteith: Daniel, any other main points?  Dr. Ontaneda: Yeah. On the side of treating relapses, I think one of the other things that probably has changed a lot, at least during the course of my training, is that in the past, whenever we had identified a relapse, as Dr. Mowry has clearly defined, we would typically treat with intravenous high-dose corticosteroids, typically with methylprednisolone. And that was kind of our go-to. We would either do it in an infusion center or we would set it up with home care. And I think one of the things that our field learned over, I would say, the last five or ten years is there's an abundance of studies that show that you can give that same dose of methylprednisolone. Rather than giving it IV, you can give it orally. No pun intended, as I tell my patients, a lot of pills to swallow because we use fifty-milligram prednisone pills, and they have to take 1,250 a day. The pharmacy always pushes back on that many pills, but really the advantage of being able to take steroids orally that way for three to five days is really, I think, one, better for people with MS because they can do it in the comfort of their own home, and two, I think also when you look at the costs associated with that treatment, it is the most cost-effective option. Dr. Monteith: And what are some of the latest developments that you're really excited about that weren't in the article?  Dr. Mowry: A lot of the article focused on the approach to treatment of people with what we've traditionally called relapsing/remitting multiple sclerosis. So, this is the kind of MS that traditionally presents with a relapse or an attack initially, although some of that nomenclature is changing, actually. And the article focused a lot on the strategies surrounding treatment of somebody with newly diagnosed relapsing MS, and thinking about this vast number of disease-modifying therapies that are available to people with MS and their clinicians, and how to think about the strategy with respect to largely centered around the efficacy class of the medication, whether people should take an approach of using a higher-efficacy therapy---meaning a medicine that in clinical trials was more likely on average to suppress relapses as well as new lesions---or whether there's still a good argument for the case of using an escalation approach, using some of the more modest efficacy medications that also probably in general have lower risks, monitoring for response to treatment and changing if the medication isn't working. And so, there's still a lot of debate in the field, I would say, even though many people have moved towards a one-size-fits-all kind of approach. I think there's still a lot of debate in the field about the evidence underlying that. And, you know, full disclosure, Dr. Ontaneda and I are each running parallel and very complementary clinical trial programs to address this very question, the results of which should be available within the next year, year and a half.  Dr. Monteith: Well, we can't wait that long. Give me some clinical pearls to how we initiate these modifying therapies. Like, what are the pearls that we need to have in our mind?  Dr. Ontaneda: Yeah. I think when we think about starting the disease-modifying therapy in an individual who has an active form of multiple sclerosis, I think, you know, one of the cornerstones I would say of making that decision is shared decision-making. I think we tend to sit down with the patient and analyze the data that we have at hand, what we know about their multiple sclerosis, and we use several factors to inform how likely we think their disease is gonna be active or potentially might not respond to the initial treatment you give. And we look heavily at the MRI. The MRI is really a useful marker because it shows us, one, how many lesions a person might have---both, you know, where those lesions are and also kind of the amount of lesions. Lesions, certainly, that are in the spinal cord, a very large burden of diseases. A lot of active lesions, which we determine by the presence of contrast-enhancing lesions, really helps us inform on disease severity. I would say that was our number one tool that we use to decide and help us decide how we think that person's MS is gonna do over time. And then the second thing that we put into the equation also is, you know, how well do we think this person is going to tolerate our medications? All our disease-modifying medications act through suppression of the immune system, and we know that that carries some risks associated with it. Some of those risks are stuff like infections. Some of those can be simple infections that really don't have major consequences, but some of them can be quite serious, including the need for hospitalizations or prolonged antibiotic treatment courses. And so, we also look at what, you know, the underlying risk of a person has for infection. This kind of is determined by, one, A, how many infections they've had up to date, and also how much disability they had. I would say in our average patient who when we see them, they're probably typically pretty young, in their twenties, thirties, forties, they typically don't have a lot of infectious risks. And therefore, I think there's kind of a move to saying, "Well, actually their risk of infections is quite low." And we put that together with, you know, also what the preference of the patient might want. So, do they prefer to take a pill, for example? Do they prefer a medication where they receive that via infusion every six months and they don't really have to think about it? There are some people that don't like going into a hospital, and they might prefer an injection type of those medications. And so, after a complex discussion of all those factors, we take into consideration how much risk the patient wants to take as well, and we come up with a rational choice of a couple of medication options. So, I think it's challenging sometimes because we have over two dozen medications. There's the risk of you saying, "There are these twenty-four medications, you can pick one." And I think our job as neurologists is to kind of pare those down, talk about, in a person like yourself, these are the two or three medications that I would recommend using. Why don't you review them? And then we bring them back, and we kind of make a final decision with, one of the key factors that I think is important to remind people is that you're gonna start this medication, and we are gonna monitor to make sure it's working. We're gonna monitor to make sure you're tolerating it well. And although it's an important, the first decision you make, I think one key theme that we tell people is, we can revise our strategy whenever we like. We just have to think about it and do it in a way that we think is gonna make sure that their MS is under the best control. And then we think about the ultimate goal of treatment, which, in multiple sclerosis, is the absence of any attacks and also the absence of any new lesions on MRI. And that's where whether you are offering more of the high-effective medications or more moderate- or low-efficacy medications, that's where there's a little bit of controversy still in our field, and that's what our trials are trying to answer.  Dr. Monteith: Excellent. So now we've selected a particular option- and I love those points with shared decision-making, using the MRI to guide and then kind of risk tolerance related to infection. But now a patient's still having relapses, and I know the goal is zero, but, you know, there's some margin. What are the pearls to advance to more high-efficacy therapies?  Dr. Mowry: Yeah, that's a great question. Dr. Ontaneda in the article actually talked about the literature surrounding monitoring for breakthrough disease and when to say this much is too much, and there's actually not a definite right answer. It's clear that more active disease early in the course is probably more of concern than, say, developing, you know, a new spot in your fifties or something to that effect. So, different people have different thresholds. I know at our center, we tend to be pretty on top of making changes for breakthrough disease. So, what we typically do is reimage people about six months after they start a medication to establish a new baseline. And sometimes, because of delays in starting or because the medications take a while to kick in, there might be a new spot or two. So, if that's the case, I really only get concerned if the spots are also taking up the dye or enhancing to indicate they're really quite recent, and I think, "Ugh, that's not something I'd like to see six months after starting a medication." And so that otherwise is sort of the reference scan, moving forward, to evaluate the medication, and I have a very low threshold for changing, particularly if somebody is on a moderate-efficacy therapy. To me, I think, well, our goal of trying the moderate efficacy therapy is essentially to see if we could get away with a medicine that is probably, on average, safer and that will still work for your MS. But if the answer is no, I personally don't like to stick around too much on them. One caveat I would say is that if somebody develops what appears to be a new lesion or spot on higher-efficacy therapy, before presuming that that new area of activity is a definite new MS event, I always like to rethink carefully, did I get the diagnosis correct? Or could this be an early infection such as, you know, progressive multifocal leukoencephalopathy in people on natalizumab in particular? Because I see breakthrough activity so rarely in people on higher-efficacy therapies that I just like to rethink my diagnosis and the differential prior to making switches to, typically, another higher-efficacy therapy in that case. But that, again, is a little bit of shared decision-making. It's sometimes contextual. If a person is using a self-administered medication and they have a little breakthrough, sometimes you can solicit some history, saying, "Oh, I actually kind of stopped taking it for a few weeks because something was going on, and I really want to retry." And that's very reasonable as well. Dan, do you have any other thoughts?  Dr. Ontaneda: No, I think I agree. That's really close to how I practice myself as well, and the majority of people at my center. I think that we are learning that when you start a treatment, many times---depending on how deeply you look---you can find evidence of ongoing disease, and that's something that we struggle with. It's almost like we have tools to treat inflammation in terms of new MS lesions and new relapses. And so, when those are present, it's pretty clear that you probably have to switch medication. I think a slightly trickier issue is when, for example, you have a person who might be stable. They don't have an attack. But you notice that they're worsening, and they tell you they're worsening. I think our ability and tools for that is a little bit harder, and we recognize that that can actually happen fairly early in the disease. And that's why we're trying to rethink this mantra that we've had for many years, where we kind of divide MS up into relapsing and progressive, and we see people develop progressive MS 10 to 15 years after they've had a relapsing form of the disease. So, I think that's just a reality of clinical practice. And we don't have as many tools to treat that gradual worsening, which is kind of what the rest of our article spent some time talking about. Dr. Monteith: You've also written about the clinical trial long-term extension studies. And what are the few points that you take away from the emergence of these types of publications over the past few years? Dr. Mowry: Yeah, well, long-term extension studies can be really helpful to understand whether the findings that are evidenced during the randomized portion of trials themselves continue into a longer term. And for people with MS, understanding these data can be really helpful because, particularly when we're looking for impact of a given treatment or a strategy on disability worsening, often it takes longer than the short-term portion of the trial to truly understand if the medication or strategy has an impact on insidious worsening that Dan is speaking about. Many trials have demonstrated a short-term benefit, but we think a lot of times that benefit is probably because of the reduction in relapses, which sometimes leave a permanent mark on neurologic function. But the extension studies are trying to understand a little bit more about whether the effect on disability worsening is sustained, and also to look a little bit more deeply at long-term safety, especially when it comes to medications that do increase the risk of infection. The caveats, though, in interpreting those types of studies are that people drop out, and so probably the people who drop out of those studies are really different. They may be either less disabled and they think, "Oh, you know, I'm done. I feel good." Or potentially more disabled and they think, "Ugh, I have more things to do I've got to take care of. What's going on?" And so that kind of dropout can produce some bias in interpreting the results. Dan, any other thoughts?  Dr. Ontaneda: No, I think that's spot on. I mean, I think that when we're trying to decide on what general philosophy to use, right? Like, you're seeing a patient for the first time. They've recently been diagnosed with MS, and you have... you know, I kind of bin them into three options. You can start a low-efficacy, a moderate, or a high-efficacy medication. And the first piece of information you could use is clinical trials, and Dr Mowry very clearly identified why some of that data might be a little bit biased and isn't, you know, completely applicable to the patient who's in front of you. The second thing that we might look at is observational data, and there's a wealth of observational data that shows that, in general, people on higher-efficacy medications tend to do better over time. But one of the challenges we have is that there's always biases related to those observational study designs. And so, I think you have to interpret them with a little bit of caution because there are reasons people start specific medications in people. And when you look at them in a purely observational study, even if you do some fancy way of addressing those biases, such as propensity, there always is the possibility of some residual bias. You know, that's part of the reason why we're doing the trials that Dr Mowry described, because we really need kind of long-term evidence to show that these medications actually can affect disability ten, twelve years after started. And I think pragmatic clinical trials, like the ones we're running, are really gonna be the key to answer those questions. We all have our favorite approaches right now, but I think that the data to actually demonstrate what's best for people with MS is really needed.  Dr. Monteith: Great, and there's so much in this article. I mean, we didn't even touch on radiological isolated syndrome, monitoring MS therapeutically, and treatment of progressive MS. Any final take-home points?  Dr. Ontaneda: Yeah. Maybe I will touch a little bit on the side of progressive MS, because it has been, you know, the MS that we historically have not been able to treat as much. So, we described there's over two dozen therapies approved for relapsing forms of MS. For purely progressive forms of MS that don't have any evidence of activity, we really only have one approved therapy, and it appears that that therapy actually does work through active inflammation anyway. And in the article, we highlighted examples of studies that have been negative, but also some recent examples of studies that have been positive, specifically with a new class of medication called BTKI, or Bruton tyrosine kinase inhibitors. We just recently heard of a second molecule that also had positive results in this realm. So, we're excited that, you know, in the next four to five years-  Dr. Monteith: I'm sorry. Can you just go ahead and say what that molecule...You're leaving people hanging.  Dr. Ontaneda: One molecule is tolebrutinib, which already has a positive study in secondary progressive MS in individuals without activity. And then the second compound that has been studied with positive trial results, we only have summary results from that, is a medication called fenobrutinib. And we think these two compounds that are part of a single class, the hope is that maybe they can address some of that gradual worsening that occurs in MS. And then the question comes whether we should use those from the get-go or if we should just use them later. So, a whole sort of variety of different questions. But I think important to call out for clinicians that this area where we had no available treatments for so many years might be changing.  Dr. Monteith: Well, thank you both. I really loved this conversation. I learned a lot listening to both of you, and I look forward to your clinical trial results.  Dr. Mowry: Thank you so much for having us. Dr. Ontaneda: Thanks so much. It was our pleasure. Dr. Monteith: Again, today I've been interviewing Doctors Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr. Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS. We're sharing details about the discovery of a new biomarker that not only confirms an MS diagnosis but also predicts the severity of an individual's disease course in the years ahead. We'll tell you about three studies focused on better managing some of the most common MS symptoms and funded by the International Progressive MS Alliance. And we'll explain how Merck and the Mayo Clinic are partnering to build a first-of-its-kind drug discovery platform using AI. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A GLP-1 for MS?  :22 I'm asking for your support:  1:31 Researchers discover biomarkers that can predict future disease course  2:13 The International Progressive MS Alliance invests $8.1 million in global studies that address the most common MS symptoms   5:44 Merck and the Mayo Clinic collaborate on AI-driven drug discovery platform  10:02 Dr. Ellen Mowry discusses the clinical trial to determine whether a GLP-1 drug can reduce inflammation in the central nervous system and offer neuroprotection to people with progressive MS  12:20 Share this episode  30:17 Next week  30:38 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/444 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms STUDY: Large-Scale Proteomics Across Neurological Disorders Uncovers Biomarker Panel and Targets in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/41747728 International Progressive MS Alliance https://progressivemsalliance.org JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 444 Guests: Dr. Ellen Mowry Privacy Policy

We are putting two episodes back into play in the feed about the unsolved murder of Catrina Mowry in the 1980s in Dallas Texas.This podcast was made possible by www.labrottiecreations.com Check out their merchandise and specifically their fun pop pet art custom pieces made from photos of your very own pets. Use the promo code CRIMEXS for 20% off a fun, brightly colored, happy piece of art of your own pet at their site.Music in this episode was licensed for True Crime XS. Our theme song is No Scars from slip.fmYou can reach us at our website truecrimexs.com and you can leave us a voice message at 252-365-5593. Find us most anywhere with @truecrimexsThanks for listening. Please like and subscribe if you want to hear more and you can come over to patreon.com/truecrimexs and check out what we've got going on there if you'd like to donate to fund future True Crime XS road trip investigations and FOIA requests. We also have some merchandise up at Teepublic http://tee.pub/lic/mZUXW1MOYxMSources:www.namus.govwww.thecharleyproject.comwww.newspapers.comFindlaw.comVarious News Sources Mentioned by NameAd Information:New Era Caps: https://zen.ai/dWeCYLHxxANOaZ6NcKocEwLiquid IV: Link: https://zen.ai/45lYmDnWl1Z3cR66LBX5mAZencastr: Link: https://zen.ai/SFkD99OGWGNz_plc2c_Yaw

Our 2025 Round Recaps and Winner Interviews are brought to you by Equinety! Use code "MoneyBarrel" at TeamEquinety.com for free shipping!Kassie Mowry wins Round 6 on "Cornbread" with a 13.42 second run!

Our 2025 Round Recaps and Winner Interviews are brought to you by Equinety! Use code "MoneyBarrel" at TeamEquinety.com for free shipping!Kassie Mowry wins Round 1 on "Will" with a 13.66 second run!

"I am gonna do what I wanna do! And you know what? I don't need your permission to do it!"What if your grandparents magically turned back into teenagers, and they were so hot that it caused chaos in your high school? And what if you look exactly like your grandma did at your age, so this magical regression inspires some twin magic hijinks? This week, The Wives Colangelo are joined by Aaron Perine of Free Space to talk about the only movie to feature all three Mowry siblings, SEVENTEEN AGAIN. Let's talk about the Tia/Tamera/Tahj trifecta, the lack of "fun" coming-of-age movies with Black protagonists, and outline all of the moments that explain why this movie was made by Showtime and not the Disney Channel.--------Become a Patron! https://www.patreon.com/thisendsatprom--------MONTHLY SPOTLIGHTDONATE TO YOUR LOCAL FOOD BANKS. GIVE THEM MONEY!--------Follow Our Guest!Free Space: https://www.howtowatchfree.tv/@HowToWatchFreeTV@Sumitlakehornet--------Social Media Plugs@ThisEndsAtProm@BJColangelo@HarmonyColangelo----------Logo Design: Haley Doodles @HaleyDoodleDoTheme Song: The Sonder Bombs 'Title': https://thesonderbombs.bandcamp.com/

It's time for a little double trouble! Mary-Kate & Ashley are on-screen simultaneously as they play the roles of "good Michelle" and "bad Michelle", while our very own Kimmy and Steph have their first real bonding moment (awww). Join us as we recap an episode filled with special effects, another failed Joey relationship and multiple Mowry's! It's all right here on How Rude, Tanneritos! Follow us on Instagram @howrudepodcast & TikTok @howrudetanneritosSee omnystudio.com/listener for privacy information.

It's another roundtable of recent comics with your hairy heavy funnybook reading homos as we say goodbye to September! Hit play to hear Steve, Caleb and Bill Z opine on new series like Cheetah and Cheshire Rob the Justice League (DC), All-New Spider-Gwen: The Ghost Spider (Marvel) and Speed Racer (Mad Cave!) We also discuss the touching done-in-one Incredible Hulk #27 (Marvel), the immensely consequential Transformers #24 (Image) and we touch base on the latest developments in the long running Something is Killing the Children (Boom Studios!)  

We have reached the end of another month and that means more Comic Book Bears Podcast audio episodes! This time around the principal focus is on the new Batman #1, the relaunch of the title from writer Matt Fraction with superstar artist Jorge Jiménez! Establishing a new status quo for the Caped Crusader and his home city of Gotham, Batman #1 from DC hits the ground running including a supporting cast shakeup and a much more high tech Batman. But that isn't the only new title discussed this time around. Hit play to hear CBB boys Bill Z, Steve and Caleb also discuss The Adventures of Lumen N (Dark Horse), No Saints Nor Poets (Tightrope Press), Hellboy in Love: The Art of Fire (Dark Horse), Everything Dead and Dying (Image) and Jeff Lemire's memoir 10,000 Ink Stains (again, Dark Horse.) 

We're raising awareness around the haunting and tragic unsolved murder of 19-year-old Michael Mowry III, who was fatally shot in his Rochester, New Hampshire, apartment during Labor Day weekend 2020. Five years later, his family is still searching for answers. Join us as we explore the new connections and details of the case (after releasing an episode in 2024), the ongoing investigation, and the heartbreaking quest for justice in the wake of this senseless crime.**A $1,000 reward is being offered for tips that lead to an arrest. Information can be reported anonymously by calling the Rochester CrimeLine or texting CRIMES with TEXT4CASH in the body of the message.**EPISODE NOTES & DISCLAIMERS:https://www.fosters.com/story/news/crime/2012/01/12/four-suspects-arrested-for-daytime/49771759007/https://www.justice.gov/usao-nh/pr/maine-man-sentenced-84-months-federal-prison-methamphetamine-traffickinghttps://www.doj.nh.gov/news-and-media/investigators-ask-tips-2020-unsolved-homicide-teen-found-shot-his-rochester-bedroomhttps://www.hgazette.com/news/local_news/haverhill-merrimack-valley-suspects-sought-in-2020-labor-day-murder/article_85f835c3-28d2-5bfa-a779-259f64241258.htmlhttps://www.fosters.com/story/news/local/2024/08/29/mom-michael-mowry-murder-rochester-nh-seeks-truth/74967200007/https://www.cbsnews.com/amp/boston/news/michael-mowry-new-hampshire-murder-cold-case/WHILE EVERY EFFORT HAS BEEN MADE TO ENSURE THE ACCURACY OF THE INFORMATION PROVIDED, WE WOULD LIKE TO EMPHASIZE THAT THE VIEWS AND EXPERIENCES EXPRESSED BY THE INDIVIDUAL ARE THEIR OWN AND DO NOT NECESSARILY REFLECT THE EXPERIENCES OF OTHERS.OPINION AND SPECULATION: THROUGHOUT THE PODCAST, THERE MAY BE INSTANCES WHERE OPINIONS AND/OR SPECULATION ARE EXPRESSED. Hosted on Acast. See acast.com/privacy for more information.

We have reached the symbolic end of Summer 2025 and the CBB Boys are back with a new audio episode. Caleb, Bill Z and Steve reconvene to discuss a set of new comics and graphic novels as we close out August. We have the Big Two represented by this year's Titans Annual from DC with Donna Troy in the spotlight with a story written and drawn by Phil Jimenez and by a new Captain America #1 from Marvel from the team of Chip Zdarsky and Valerio Schiti. We have Oni's EC Comics revival represented by Catacomb of Torment #1 and Cruel Universe #1. We also have the manga body horror of Brain Damage by Shintaro Kago and the-coming-of-gay-age of Mike Curatoro's Gaysians graphic novel. So hit play and enjoy two hours of funnybook chatter as this summer sunsets.   

The CBB Boys head back to the movies, this time for for The Fantastic Four: First Steps!!! TFF:FS is the 37th film in the Marvel Cinematic Universe franschise and the second reboot of the Fantastic Four for the cinema. The film was directed by Matt Shakman and features an ensemble cast including Pedro Pascal, Vanessa Kirby, Ebon Moss-Bachrach, and Joseph Quinn as the family-based super-hero foursome, alongside Julia Garner, Sarah Niles, Mark Gatiss, Natasha Lyonne, Paul Walter Hauser and others. Set in the early 1960s of a retro-futuristic world, the film finds the Fantastic Four desperate to protect Earth from the planet-devouring cosmic force known as Galactus! Steve, Caleb and Bill Z are all on hand to discuss what they thought of the movie and, as is our custom with our movie centered episodes, spend the back half of the show discussing collected editions featuring the Fantastic Four in comic form whuch you might enjoy! So, hit play and Flame On with this group of hairy heavy homos!

Do you ever feel intimidated when reading the Bible on your own? You're not alone. Many of us want a deeper connection with God's Word but find ourselves relying on devotionals or simply reading for information, without letting it truly change us. Well today, The Navigators' very own Bill Mowry will help you shift that mindset.  He shares five powerful practices to help you encounter God every time you open the Bible. You'll love his simple and memorable hand illustration, the four heart-check questions to ask before you even begin reading, and his practical encouragement for preparing both your posture and mindset. Whether you're a first-timer who wants to learn how to personally engage with God's Word—or you're a seasoned Bible geek who wants to fall in love with Scripture all over again—this conversation is for you. So grab your Bible, listen in, and get ready to hold the Word in a whole new way. SHOW NOTES: 413Podcast.com/363  Enter to win the GIVEAWAY and read the episode TRANSCRIPT in the show notes. Get my weekly email, Java with Jennifer, to be notified when a new podcast episode releases. Subscribe HERE.

This new Comic Book Bears Podcast audio episode is a little bit different. We were down to two bears in the cave this week so we elected to use this time together as a "backdoor pilot" for Steve Mowry's new horror-centered podcast The Bear Cave of Terror. BCOT will be available in its own feeds going forward but with Bill Z as the first of Steve's guest co-hosts, we are thrilled to present you our discussion of the seminal 1975 film Jaws as it celebrates its 50th anniversary this summer! Jaws was the first wide-release summer blockbuster which changed the way films were marketed forever and established its director Steven Spielberg as a major figure in filmmaking! We discuss the book that the film was based on, the cast, the later imitators and (of course) the scares!!! However we still were able to get a little bit of comic book talk in as well, with the first issues of The New History of the DC Universe and Lazarus Fallen by Greg Rucka and Michael Lark from Image Comics getting the CBB chat treatment! So hit play and, for one hour and fifty minutes, DON'T GO NEAR THE WATER!      

We could not wait to bring you this episode!!!  Superman, the new film, is written and directed by James Gunn and is the kickoff movie for the new DC Universe media franchise! David Corenswet stars as Superman/Clark Kent, alongside Rachel Brosnahan as Lois Lane, Nicholas Hoult as Lex Luthor along with Edi Gathegi, Anthony Carrigan, Nathan Fillion, Isabela Merced and others. In the film, Superman must prove to a suspect world that he is a protector after billionaire Lex Luthor enacts a plan to turn public opinion against him. Be forewarned, this episode is COMPLETELY spoileriffic! We all weigh in on what we thought of the movie and, as has become customary for our film-centric episodes, we also offer up our suggestions of collected editions starring the characters from the film - in this case The Man of Steel, Superman: Birthright and Superman: Lost - that we hope you might enjoy! So, hit play and ... LOOK UP!    

New Comic Book Bears Podcast audio episode! On June 19th, CBB boys Steve and Bill Z were actually together in the same place for this mini-episode previewing HeroesCon in Charlotte which ran from June 20th-22nd! Though sadly Caleb-less, hit play to hear what we had planned for the con ... and you won't have to wait too long for the follow-up as our post-convention wrap up episode is following right behind this one tomorrow!  

To finish out Pride Month we have another new Comic Book Bears Podcast audio episode! Bill Z and Steve share their HeroesCon experience in Charlotte in the beginning of the episode. And though Caleb was not with them for the con, he is back with them on the mic to discuss a series of new books! We first cover this year's Pride Month anthology offerings from the Big Two - Marvel United: A Pride Special #1 and DC Pride 2025! The queer anthology talk continues with a discussion of Young Men in Love: New Romance (Wave Blue World), and the new book chat is rounded out by Blood Type #1 (Oni), Whatever Happened to the Crimson Justice #1 (Mad Cave) and the last few issues of Namor (Marvel) - so hit play to enjoy two hours of The Heroes and The Gay!  

In 1996, Dave Mowry had a total breakdown. He was driving down the freeway. under a lot of stress, and his mind was racing. And then, his mind snapped. He heard it like a snapping twig and felt it like a small electric shock in his brain. He was broken. He lost everything and was homeless for 18 months. He was living in hell for 14 months. Dave Mowry's story is one that you will want to share with anyone who is struggling with or has a family member battling mental illness. His story is one of inspiration, healing, and hope. He has lived with bipolar disorder and severe anxiety his entire adult life. He was a successful businessman until he lost it all due to mental illness. After 14 lost years and being homeless with his family for 18 months, Dave took a stand-up comedy class for people with a mental illness. It changed everything. He went from his mental illness having control over him to finding the humor in his experiences and regaining control of his life. Dave teaches stand-up comedy to people with a mental illness and performs on stage. We find humor in our pain and tell our stories one joke at a time. We let people know that they are not alone and that it is okay to laugh about our challenges, and shatter stigma. Winner: Best bipolar disorder books of all time by BookAuthority. What started as a couple of blog posts blossomed into a following of over one million people who have read and been touched by Mowry's stories. The most extraordinary thing he found when writing about his experiences is that the most common comment about his work is "OMG, that's me". You are telling my story. I don't feel so alone now. Living with mental illness is hard, but it's especially difficult when dealing with more than one condition at the same time. Many books about coping with mental illness focus on one disorder, such as anxiety, panic attacks, or depression. Because Dave Mowry didn't see any that dealt with his situation of living with multiple disorders simultaneously, he decided to write about it himself. OMG That's Me! It is sometimes funny, often poignant, but always deeply honest, open, and personal. Mowry's stories let others know there is help and there is hope, and that they too can recover and live a full life. This book is a must-read for family members and friends who will gain true insight into the experiences of loved ones living with a mental illness. This book is a must-read for mental health professionals who will better understand the symptoms faced by their patients. And ordinary people will see the strength, resilience, and beauty of people who will shatter the stigma surrounding mental illness.

In 1996, Dave Mowry had a total breakdown. He was driving down the freeway. under a lot of stress, and his mind was racing. And then, his mind snapped. He heard it like a snapping twig and felt it like a small electric shock in his brain. He was broken. He lost everything and was homeless for 18 months. He was living in hell for 14 months.     Dave Mowry's story is one that you will want to share with anyone who is struggling with or has a family member battling mental illness. His story is one of inspiration, healing, and hope. He has lived with bipolar disorder and severe anxiety his entire adult life. He was a successful businessman until he lost it all due to mental illness. After 14 lost years and being homeless with his family for 18 months, Dave took a stand-up comedy class for people with a mental illness. It changed everything. He went from his mental illness having control over him to finding the humor in his experiences and regaining control of his life. Dave teaches stand-up comedy to people with a mental illness and performs on stage. We find humor in our pain and tell our stories one joke at a time. We let people know that they are not alone and that it is okay to laugh about our challenges, and shatter stigma.       Winner: Best bipolar disorder books of all time by BookAuthority. What started as a couple of blog posts blossomed into a following of over one million people who have read and been touched by Mowry's stories. The most extraordinary thing he found when writing about his experiences is that the most common comment about his work is “OMG, that's me”. You are telling my story. I don't feel so alone now. Living with mental illness is hard, but it's especially difficult when dealing with more than one condition at the same time. Many books about coping with mental illness focus on one disorder, such as anxiety, panic attacks, or depression. Because Dave Mowry didn't see any that dealt with his situation of living with multiple disorders simultaneously, he decided to write about it himself. OMG That's Me! It is sometimes funny, often poignant, but always deeply honest, open, and personal. Mowry's stories let others know there is help and there is hope, and that they too can recover and live a full life. This book is a must-read for family members and friends who will gain true insight into the experiences of loved ones living with a mental illness. This book is a must-read for mental health professionals who will better understand the symptoms faced by their patients. And ordinary people will see the strength, resilience, and beauty of people who will shatter the stigma surrounding mental illness.

We move into a new season and the Comic Book Bears are back with this new summer-sized audio episode! Hit play to hear Steve, Caleb and Billy Z talk about a number of new books and graphic novels! From the Big Two we explore the newest iteration of Giant-Size X-Men from Marvel and DC's The Power Company Re-Energized #1. On the independent side of things we dig into The Fairy Godfather by Robert Mailer Anderson and Jon Sack, Muybridge by Guy Delisle, Pure Rubbish by Kayla E. and the first issue of Mad Cave's Vanishing Point by Mark Russell and Juan Doe! (All this plus Caleb gets schooled about New Jersey's Pine Barrens!)    

The CBB Boys head back to the movies and discuss Thunderbolts*, the 36th film in the Marvel Cinematic Universe on this latest audio episode! The movie is directed by Jake Schreier and stars an (amazing) ensemble cast including Florence Pugh, Sebastian Stan, Wyatt Russell, Olga Kurylenko, Lewis Pullman, David Harbour, Hannah John-Kamen and Julia Louis-Dreyfus! Thunderbolts* finds the unlikely team of Yelena Belova, Winter Soldier, U.S. Agent, Taskmaster, Ghost, Red Guardian and ... Bob ... brought together by circumstance and conspiracy and discovering just what this collective of anti-heroes are capable of! And as is our tradition, each of us (Steve, Caleb and Billy Z) make recommendations of comic book arcs featuring the film's characters which we think you may enjoy! Afterwards, we go on to discuss some new comics we are enjoying - the newest version of Heavy Metal magazine, DC's Absolute Martain Manhunter and Dynamite's new Herculoids series. We hope you will hit play to join us for some Marvelous Marvel Misfit Musings and More!!!

We welcomed Clay Mowry, the new CEO of AIAA, to the program to discuss the "new" AIAA and the health of all aspects of our space industry. We started the 66 minute discussion with a detailed look at the dynamite new AIAA logo and the story about it told by Clay. First, check out the new logo. Visit AIAA.org to see it. Next, listen to Clay's story while you are looking at the new logo. If you are so inclined, post your thoughts about it on our blog for this show or in the Substack comments section (doctorspace.substack.com). By the way, how many of you remember the BellX-1 and its sound breaking history? If not, this would be a good time to learn and seal to your memory this important part of our nation's and really the worlds history. We moved on to talk about the split with AIAA between Aviation and Space. Aviation has always dominated the AIAA but as you will hear, space is becoming a more and more significant part and focus of the organization. Clay was asked about his plans going forward for the organization. In just a few words, AIAA is reaching out to its younger membership, students and going digital with most of their product. Clay told us the story about his trip to many of the nations finest aerospace engineering and science programs to interview the students to get a handle on how to focus the "new" AIAA. After telling us all about what they are doing for student and younger folk retention, a listener asked him what they were doing for the older crowd, even the "geezers." Don't miss this part of the AIAA new outreach program. In addition to the AIAA part of our discussion, Clay was asked about his views on the space economy, the continued availability of investment and risk capital, Artemis, Starship, the SLS-Gateway program and hardware plus Mars and the possible increase in attention to human spaceflight by NASA. We talked about the potential science and other agency budget cuts, we switched over to hear about the new changes and improvements for their great magazine/journal, "Aerospace America." Also, the AIAA book publishing division. He suggested we all sign up for "MyDailyLaunch (see he program to find out. Thank you. Dr. Spacehttps://aiaa.org/news/newsletters/my-daily-launch). Near the end of our program, Clay was asked what his biggest surprise was in becoming the new CEO. Well, its a surprise. Listen to the program to find out. Thank you. Dr. Space.

We welcomed Clay Mowry, the new CEO of AIAA, to the program to discuss the "new" AIAA and the overall health of our space industry. The 66-minute conversation kicked off with an in-depth look at AIAA's dynamic new logo and the story behind it, as told by Clay. Make sure you are looking at the new logo when Clay tells its story. Check it out at www.aiaa.org.First things first:First, visit AIAA.org to check out the new logo. Then, while you're viewing it, listen to Clay's story about its design and meaning. We'd love to hear your thoughts—feel free to share them in the comments on our show blog or on our Substack: doctorspace.substack.com. You will hear about the connection to the Bell-X-1. How many of you remember the Bell X-1 and its sound barrier-breaking legacy? If you don't, this is the perfect time to learn about this iconic chapter of not only U.S. history but global aerospace history.We then moved into a discussion about the changes within AIAA which is both an aviation and space organization. Clay provided us with the AIAA history but he also told us that the space division has a growing prominence of within the organization. As Clay explained, space is becoming a major focus in our economy and world and AIAA reflects that shift.When asked about his vision moving forward, Clay emphasized outreach to younger members, especially students, and a strong push toward digital transformation. He shared his experiences visiting many of the country's top aerospace engineering and science programs, where he listened directly to students to better shape AIAA's future direction. Be sure to listen what he said about how where most students get their news and information.After exploring AIAA's plans for student engagement and youth retention, one listener asked an important question: What about the older members—the "geezers" of the community? Don't miss this part of the show, where Clay addresses AIAA's outreach to its more seasoned members.In addition to discussing AIAA's internal evolution, Clay shared his insights on broader industry topics including:* The space economy* Trends in investment and risk capital* The Artemis program* Starship, SLS, and the Gateway program* NASA's increasing focus on human spaceflight* Potential budget cuts affecting NASA science and other agenciesWe also covered exciting updates to Aerospace America, AIAA's flagship magazine and journal, as well as their book publishing division. Clay encouraged everyone to subscribe to My Daily Launch, AIAA's newsletter. You can find it here:

It is hard to believe that it has been over four years since our special group of Star Wars fans (Mike Lovins and Craig Lantz joining CBB regulars Steve Mowry and Bill Zanowitz) have been gathered around the mic together, so we are thrilled to bring this Force Sensitive Foursome back on this new audio episode! We very recently saw the second season of Andor begin with the first three episodes released at once. We weigh in on that (in a totally spoilerific fashion), the news from Star Wars: Celebration 2025 from Tokyo and a whole lot more!  So power down your lightsabers, set your blasters on stun, hit play and enjoy our musings on tales from a galaxy far, far away!    

It has been a few years since we had a Comic Book Bears Podcast episode wholly dedicated to manga and figured it was time for a new one! So hit play to join in on 2+ hours of chatter about some great works, old and new, that have come out of Japan! The CBB Boys - Bill Z, Steve and Caleb - have chosen Frieren: Beyond Journey's End, Wild Strawberry, Mach GoGoGo (aka Speed Racer), The Liminal Zone, Astro Baby and Inuyashiki as the subjects for this particular summit!  ショーを楽しんでいただければ幸いです。

How can humor help you with depression and anxiety?Meet Dave Mowry!Dave is an Author of 2 books about living with a mental illness. OMG That's Me! and OMG That's Me! 3. Teacher of stand-up comedy to folks with a mental illness, Co-executive director at NAMI, and popular podcast guest.What started out as a couple of blog posts blossomed into a following of over 1,000,000 people—who have all read and been touched by Dave's stories. The most extraordinary thing he found when writing about his experiences is that the most common comment about his work is “OMG that's me. You are telling my story. I don't feel so alone now.”Living with mental illness is hard, but it's especially difficult when dealing with more than one condition at the same time. Many books about coping with mental illness focus on one disorder, such as anxiety, panic attacks, or depression. Because Dave Mowry didn't see any that dealt with his situation of living with multiple disorders simultaneously, he decided to write about it himself.Additional Resources:"OMG That's Me!: Bipolar Disorder, Depression, Anxiety, Panic Attacks, and More" by Dave MowryListen to the Podcast, leave a rating and a review:Apple:  https://podcasts.apple.com/us/podcast/depression-and-anxiety-humor-therapy-for-your-mental/id1614151066?i=1000701685747Spotify:  https://open.spotify.com/episode/49yDpUGHKTpgVkMdTGOzTq?si=YTZR0mPfSiuszsP43FDMYQhttps://open.spotify.com/episode/49yDpUGHKTpgVkMdTGOzTqYouTube: https://youtu.be/AKWmRPjLWzY?si=fNHQJ_i-Nw5_rH3y

Through new tattoos, foot injuries and holding down the fort at home, Bill Z, Steve and Caleb return with another new Comic Book Bears audio episode! After a little bit of catching up with each other and a little bit of news (a new DC/Marvel crossover planned for the summer, Daredevil: Born Again), the CBB Boys dive into comic talk. And it's a varied grouping this time around - from the latest Green Lantern Corps relaunch (DC) to the Captain America and Volstagg one-shot (Marvel) to Ashes by Àlvaro Ortiz (Top Shelf) to Final Cut by Charles Burns (Pantheon) to some manga with The Marshal King by Boichi (Viz) and wrapping up with the Techno-Noir of Warm Fusion by Scott Hoffman and Alberto Ponticell (DSTLRY)! Hit play for 2+ hours of funnybook talk from some hairy, heavy homos!

Spring has sprung and March is in its "out like a lamb" phase and the CBB Boys (Steve, Caleb and Bill Z) are back with a new audio episode! For a change there is a good deal of comics related news between Diamond's auction completing, the cast roll out for Avengers: Doomsday and the New History of The DC Universe and we cover each of these at the beginning of our show. Then onto the new comic talk with Avengers #21 (with an Avengers vs X-Men baseball game), the X-Men's X-Manhunt event, Zatanna #1, Secret Six #1, the Gargoyles: Winter Special and the Resurgence of the Valiant Universe mini-series all having their moment under our ursine spotlight!

You know him from Full House as Michelle's lovable BFF "Teddy", but that's just the tip of the iceberg when it comes to Tahj Mowry's incredible career! Remember "Smart Guy"?! How about "Baby Daddy"? You likely know "Kim Possible"! And, we can't forget Jodie's personal favorite, "The Muppets Mayhem"!! We can't wait for all of you Fanneritos to get a glimpse into Tahj's experience on these projects, what it was like growing up in the Mowry household and, of course, his favorite memories from Full House! It's an interview that's sure to brighten your spirits, so you can't miss it! It's all right here on How Rude, Tanneritos! Follow us on Instagram @howrudepodcast & TikTok @howrudetanneritos See omnystudio.com/listener for privacy information.

Time for a new Comic Book Bears Podcast audio episode!  Steve, Caleb and Billy Z reconvene for two hours of four color funnybook talk! On the docket this time are a few news items (Diamond's bankruptcy, Marvel Studios not inviting Rob Liefeld to an afterparty) followed by a half dozen books we wanted to spotlight. Hit play and hear about what we thought of the inaugural issues of a few new series: Aquaman (DC), West Coast Avengers (Marvel), Lawful (Boom!) and The Death of COPRA (Image). We also chat about Tim Bird's autobiographical graphic novel Adrift in a Painted Sea (Avery Hill Publishers) and DC's tabloid reprinting of the 1980 Untold Legend of The Batman mini-series. Also, please note that this episode was recorded at the beginning of the month and as 2/3rds of the team here are huge football fans we offer up what were our Super Bowl LIX predictions. (One of us gets it spectacularly wrong.)  

The Comic Book Bears podcast goes All In this time around in our new audio episode! As much of the US is contending with a January winter freeze, Bill Z, Steve and Caleb once again huddle around the mic. And after a deep dive into recent news (specifically Diamond Comic Distributors filing for Chapter 11 bankruptcy and the allegations by various women against Neil Gaiman), the CBB boys turn their attention to DC Comics and their All In publishing initiative which finds their entire main comics line enjoying a refresh! Justice League Unlimited, Justice League: The Atom Project, Action Comics, Birds of Prey, New Gods and Metamorpho are the main books discussed. And all you have you have to do is hit the play button to go All In with us!

The CBB Boys are thrilled to bring you the audio version of their 300th episode! And for this anniversary they welcome back to the show a very familiar name and a great friend - writer Richard Rivera! Richard is here to chat about his new Kickstarter for the latest Stabbity Bunny project: a remastered version of Stabbity Ever After #1 which takes Stabbity on a more humorous path through an alternative reality. But this time Richard brings along some friends to the show with their own Kickstarter campaign! Making their CBB debut to discuss it are writers and Insymmetry Creations co-founders Matt Knowles and Steph Cannon! Matt and Steph take us into the world of Heirs of Isildur, a collision of sci-fi, steampunk, heavy metal and graphic storytelling that is on its fourth issue! Heirs of Isildur is not the only project under the Insymmetry Creations banner and we also get to hear about a number of those. And best of all, there is a campaign component where Stabbity and Isildur crossover!!! (Links to the Kickstarter campaigns are below in the comments!) Afterwards Steve, Caleb and Bill Z launch into an unexpected Manga tangent and roundtable a few new comics including Wonder Woman (DC), The Question: All Along the Watchtower (DC) and Maria Llovet's Violent Flowers (Image) - so hit play and enjoy two hours and 34 seconds of hairy, heavy, Kickstartery anniversary goodness!!!

This new Comic Book Bears audio episode is our last episode of 2024 and a loaded one it is! The CBB trio of Caleb, Bill and Steve are all on hand to chat about a whole bunch of things! The teaser trailer for the upcoming Superman film written and directed by James Gunn dropped on December 19th and this turned out to be a very big deal. We opine on it along with the new Creature Commandos animated series on Max which kicks off this new DC Universe for film and TV. In terms of Marvel, in the movie theaters right now is Kraven the Hunter - the new film based on the Spider-Man adversary starring Aaron Taylor-Johnson in the title role, Ariana DeBose and Russell Crowe. 66.6% of the bear crew saw it and provide their viewpoints on it. We also take a few new books off of the virtual spinner rack and discuss JSA by Jeff Lemire and Diego Orlotegui (DC), Arcbound by Tom Hardy, Scott Snyder, Frank Tieri and Ryan Smallman (Dark Horse) and Tender by Beth Hetland from Fantagraphics. Lastly, each of us choose their favorite series or graphic novel of 2024 which were ... well, you will just have to hit play to find out what our picks were! Hoping you all are having a great holiday season and our best wishes to you in 2025!

The Comic Book Bears shake off the snow and ice from their fur ... well, two of them do at least ... to regroup to chat about some new comics now that winter has hit! One of them is DC's Absolute Wonder Woman! Three more of them are from Image: The Department of Truth, Falling on Love on the Path to Hell and Grommets! Another is a new interpretation of Dracula courtesy o Matt Wagner and Kelley Jones! And we also chat about Being Gordy, a situation comedy in comic book form! So heat up some hot chocolate (or whatever your favorite wintertime drink is), hit play and enjoy!

This podcast features Jim Reske interviewing Christian author Bill Mowry, discussing his book, The Ways of the Leader. Mowry's discussion centers on the importance of wisdom in leadership, emphasizing four key practices: lifelong learning, collaboration, cultural understanding, and innovation. He illustrates these concepts through personal anecdotes and biblical references, highlighting the need for humility and a commitment to continuous growth. The interview also touches on Mowry's background with the Navigators, a Christian discipleship organization, and his approach to developing leaders who can effectively address local challenges. Finally, the hosts encourage listeners to engage with the Gospel and promise a future podcast episode.

This podcast features a conversation between Jim Reske and Bill Mowry, who discuss Bill's book, "The Ways of the Leader," focusing on cultural wisdom and leadership. Mowry's concepts of becoming a "cultural detective" to understand different environments and the importance of asking insightful questions are explored. The discussion highlights the challenges and rewards of applying biblical principles in diverse cultural contexts, contrasting a confrontational approach with one of understanding and adaptation. Finally, the conversation emphasizes the pursuit of wisdom as an active and vital process.

This podcast features Jim Reske interviewing Bill Mowry discussing leadership qualities, emphasizing the primacy of character over competence, drawing from their study of the Pastoral Epistles. They further explore the concept of lifelong learning, highlighting the importance of slowing down to observe and reflect, contrasting this with the fast-paced nature of modern culture. The discussion then expands to encompass collaboration as a leadership style, contrasting it with other approaches, and the significance of inclusion within a team. Finally, the hosts illustrate how to integrate innovative approaches to ministry while maintaining core biblical truths.

This podcast features an interview with Bill Mowry, a Christian author and long-time staff member with the Navigators. Mowry shares his testimony and discusses his book, The Ways of the Leader, which focuses on developing wisdom in leadership. He emphasizes the importance of practical, locally relevant solutions rather than relying solely on outside experts. The conversation explores the concept of wisdom as a skill, highlighting the need for humility and continuous learning in leadership. The hosts also discuss Mowry's work with the Navigators and the discipleship principles.

These nightly recaps and interviews with the round winners are brought to you by Equinety! Round 8 winners - Shelley Morgan and Kassie Mowry

These nightly recaps and interviews with the round winners are brought to you by Equinety! Round 7 Winner - Kassie Mowry and "Jarvis"

These nightly recaps and interviews with the round winners are brought to you by Equinety! Round 6 winner - Kassie Mowry and "Jarvis"

These nightly recaps and interviews with the round winners are brought to you by Equinety! Round 5 winner - Kassie Mowry and "Jarvis"

These nightly recaps and interviews with the round winners are brought to you by Equinety! Round 4 winner - Kassie Mowry and "Jarvis"

Hi Listeners! You'll love today's story of triumph and humor! Dave Mowry shares his vulnerability story about his journey with lifelong Bipolar Disorder and Severe Anxiety. From losing his home and job to writing and helping others in their own similar journeys, he found that using humor gave him so much healing. Dave's book, "OMG, That's Me" available on Amazon. www.bphope.comwww.davemowry2@gmail.com#applepodcasts #ineverknewbutmydogdidpodcast#lifecoachmaureen #inspirationalstoriesBecome a supporter of this podcast: https://www.spreaker.com/podcast/i-never-knew-ink-but-my-dog-did-by-lifecoach-maureen--5602763/support.

In our first Comic Book Bears audio episode recorded after the US election, the CBB boys (Bill Z, Caleb and Steve) spend the first few minutes talking about the results and the state of the nation. We then (mercifully) put that to the side to chat about some recent comics. And what a line up we have! Absolute Superman #1! DC Horror Presents Creature Commandos #1! Animal Pound, written by Tom King and published by Boom! The Magic Fish by Trung Le Nguyen! Horny & High, Volume I by Ed Firth from our good friends at Northwest Press! And the new Jonny Quest series from Dynamite! Hit play and enjoy!

Merry and Cathy welcome comedian and author Dave Mowry, who shares his incredible journey from a mental breakdown and severe depression to finding joy through stand-up comedy. Discover how Dave transformed his life using humor to manage bipolar disorder, PTSD, and anxiety and how he's helping others do the same. Tune in to hear inspiring stories and get a dose of resilience, laughter, and hope; and please connect with us on Lateboomers.biz to share your own stories! Dave Mowry's Bio:Dave lives with bipolar disorder and severe anxiety and has all his adult life. He was a successful businessman until he lost it all due to his mental illness.At 59, after 14 lost years, including 18 months of being homeless with his family, Dave took a stand-up comedy class for folks with a mental illness. It changed everything. Dave went from his mental illness having control over him to finding the humor in his experiences and regaining control of his life.Today Dave teaches stand-up comedy to other folks with a mental illness and performs on stage. telling his story one joke at a time. He is also co-executive director of a mental health nonprofit.Dave is the author of the best-selling book, OMG That's Me! Bipolar Disorder, Depression, Anxiety, Panic Attacks, and more... which has sold over 17,000 copies. Dave is co-author of OMG That's Me! 3, and is working on his next book, Healing with Humor.Dave blogs for bphope.com where his posts have been read by over a million people with the most common comment being "OMG That's Me! you're telling my story, I don't feel so alone now."At 72, Dave has no plans on slowing down anytime soon.Connect with Dave:- Dave's Book: OMG That's Me!: Bipolar Disorder, Depression, Anxiety, Panic Attacks, and More- Website: www.bphope.com/author/david-mThank you for listening. Please check out @lateboomers on Instagram and our website lateboomers.biz. If you enjoyed this podcast and would like to watch it or listen to more of our episodes, you will find Late Boomers on your favorite podcast platform and on our new YouTube Late Boomers Podcast Channel. We hope we have inspired you and we look forward to your becoming a member of our Late Boomers family of subscribers.

AITA: For being mad at a dog owner? Dirt Alert: Tia and Tamara Mowry beef, TV TASTE TEST: "My Three Daughters," and "Monsters," and Oasis reunion news! Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AITA: For being mad at a dog owner? Dirt Alert: Tia and Tamara Mowry beef, TV TASTE TEST: "My Three Daughters," and "Monsters," and Oasis reunion news! Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, I'm thrilled to introduce you to Dave Mowry, a man who transformed his life from the depths of bipolar disorder and severe anxiety to a beacon of hope and inspiration. After losing everything, Dave found his way back through the power of stand-up comedy, using humor to heal and to help others shatter the stigma surrounding mental illness. Join us as Dave shares his incredible journey from a successful businessman to a man who found his purpose in the most unexpected way—on stage, making people laugh. We'll dive into how stand-up comedy gave him control over his life, and how he now teaches others living with mental illness to find humor in their pain. Dave also talks about his bestselling book OMG That's Me! and the impact it's had on readers worldwide. We'll discuss everything from the hardest he's ever bombed on stage to the progress he's seen in the fight against mental health stigma. Dave's story is one of resilience, laughter, and hope, and it's sure to leave you feeling inspired. Whether you're dealing with mental health challenges yourself or simply want to understand the healing power of comedy, this episode is a must-listen. Topics Covered: Dave's journey from losing everything to finding purpose through comedy. The role of humor in mental health recovery. Memorable moments from teaching stand-up to those with mental illness. Insights into his book OMG That's Me! and its impact. Navigating the fine line between humor and sensitivity in mental health topics. The evolution of public perception around mental illness. Tune in for a powerful conversation that will make you laugh, reflect, and believe in the possibility of finding light in the darkest of places. Find Dave's books and more here: OMG Don't miss out on this inspiring episode! Please support my sponsors! I know them all personally and can vouch for their integrity and quality. -For website design, graphic design, internet marketing, and more check out McWilliams Marketing at⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠http://www.McWilliamsmarketing.com⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠ -Use Patnaik Realty for ANY real estate needs you have. I mean anything! Residential, commercial, property management, investments, acquisitions. He does it all.  Call Teek at 256-694-0117 or e-mail him at Teek@PatnaikCo.com⁠⁠ -My new book "You're Not Who You're Going To Be" is available on Amazon! --->⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shorturl.at/U8vTu